# A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

> **NCT00612118** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (actual)

## Conditions studied

- Allergic Rhinitis
- Rhinitis, Allergic, Seasonal

## Interventions

- **DRUG:** GSK256066
- **DRUG:** azelastine hydrochloride

## Key facts

- **NCT ID:** NCT00612118
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612118, "A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00612118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*